Mazen Noureddin

Appearances

DEBATE: TRADITIONAL VS ENDOSCOPIC APPROACH FOR THE DIAGNOSIS OF NAFLD
Date
May 7, 2023
SOCIETY: DDW
Presenters
Mazen Noureddin
Mark A. Gromski
Indiana University School of Medicine
IS LIVER BIOPSY DEAD?: BEST PRACTICE IN USING NITS VERSUS BIOPSIES
Date
May 6, 2023
SOCIETY: AASLD
Presenter
Mazen Noureddin
CASE-BASED SYNTHESIS: HOLISTIC CARE OF THE PATIENT WITH CHRONIC LIVER DISEASE
Date
May 21, 2024
Presenter
Mazen Noureddin
ALT, FIBROSCAN VCTE, AND FIBROSCAN CAP AS PREDICTIVE MARKERS OF RESMETIROM BIOPSY RESPONSE
Date
May 19, 2024
INTRODUCTION. MAESTRO-NASH (NCT03900429) is an ongoing 54-month, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy of resmetirom in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis…
Presenter
Rohit Loomba
University of California San Diego
Speakers
Jorn Schattenberg
Rebecca Taub
Dominic Labriola
Mazen Noureddin
Vlad Ratziu
Stephen Harrison
THE LANDSCAPE OF NON-INVASIVE TESTING FOR MASLD
Date
May 20, 2024
Presenter
Mazen Noureddin
ATTENTION ON MASH: EXPLORING THE ROLE OF METABOLIC DYSFUNCTION IN A CHRONIC LIVER DISEASE
Date
May 21, 2024
Presenter
Mazen Noureddin
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
Date
May 21, 2024
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
Presenter
Naim Alkhouri
Speakers
Mandy Fraessdorf
Guy Neff
Joern Schattenberg
Mazen Noureddin
Eric Lawitz
Quentin Anstee
Elisabetta Bugianesi
Samina Ajaz Hussain
Philip Newsome